The main reason why BRAFV600E-treated colorectal cancer (CRC) develops drug resistance to selective BRAF inhibitors is that BRAF inhibitors can induce autophagy through the AMPK-ULK1 pathway [172]. Here, BRAF is linked to colorectal cancer.